急性肾损伤期间CT碘对比剂累积暴露与主要不良肾脏事件
该倾向性评分匹配分析纳入1127例KDIGO标准定义的急性肾损伤患者,将419例围急性肾损伤期接受CT对比剂暴露者与798例未暴露对照按14项协变量匹配。结果显示累积CT对比剂>100 mL与主要不良肾脏事件独立相关(OR 2.39,p=0.005),而≤100 mL与主要不良肾脏事件无关联;对比剂暴露者晚期肾功能恢复更多(27% vs 20%)、住院时间更长(中位10天 vs 8天)。
要点
- 急性肾损伤期间累积CT碘对比剂>100 mL与主要不良肾脏事件独立相关(OR 2.39,p=0.005)。
- 累积CT对比剂≤100 mL者主要不良肾脏事件风险与未暴露对照无显著差异。
- 对比剂暴露者晚期肾功能恢复更多(27% vs 20%)、住院时间更长(中位10天 vs 8天)。
诊断标准与关键数值
- 主要不良肾脏事件为死亡、肾脏替代治疗和出院时血清肌酐较基线倍增的复合终点。
- 肾功能恢复根据急性肾损伤起病至肌酐最低点或存活者停止肾脏替代治疗的7天时间线分为早期与晚期。
- 累积CT对比剂>100 mL者主要不良肾脏事件发生率为34%,>50-100 mL者为17%,≤50 mL者为21%,未暴露对照为20%(>100 mL vs 无对比剂 p=0.008)。
- 多变量分析中,累积CT对比剂>100 mL与主要不良肾脏事件独立相关(校正所有混杂因素后OR 2.39 vs 无对比剂,p=0.005);累积CT对比剂<100 mL与主要不良肾脏事件无关联。
临床应用与阅片要点
- 对急性肾损伤患者阅片及报告时,应关注并记录CT检查中碘对比剂的累积给药体积。
- 累积CT对比剂>100 mL与主要不良肾脏事件独立相关,≤100 mL者主要不良肾脏事件风险与未暴露者无显著差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine if contrast-enhanced CT imaging performed in patients during their episode of AKI contributes to major adverse kidney events (MAKE).
METHODS: A propensity score-matched analysis of 1127 patients with AKI defined by KDIGO criteria was done. Their mean age was 63 ± 16 years with 56% males. A total of 419 cases exposed to CT contrast peri-AKI were matched with 798 non-exposed controls for 14 covariates including comorbidities, acute illnesses, and initial AKI severity; outcomes including MAKE and renal recovery in hospital were compared using bivariate analysis and logistic regression. MAKE was a composite of mortality, renal replacement therapy, and doubling of serum creatinine on discharge over baseline; renal recovery was classified as early versus late based on a 7-day timeline from AKI onset to nadir creatinine or cessation of renal replacement therapy in survivors.
RESULTS: Sixty-two patients received cumulatively > 100 mL of CT contrast, 143 patients had > 50-100 mL, and 214 patients had 50 mL or less; MAKE occurred in 34%, 17%, and 21%, respectively, as compared with 20% in non-exposed controls (p = 0.008 for patients with > 100 mL contrast versus none). More contrast-exposed patients experienced late renal recovery (27% versus 20%) and longer hospital days (median 10 versus 8) than non-exposed patients (all p < 0.01). On multivariate analysis, cumulative CT contrast > 100 mL was independently associated with MAKE (odds ratio 2.39 versus non-contrast, adjusted for all confounders, p = 0.005); cumulative CT contrast under 100 mL was not associated with MAKE.
CONCLUSIONS: High cumulative volume of CT contrast administered to patients with AKI is associated with worse short-term renal outcomes and delayed renal recovery.
KEY POINTS: • Cumulative intravenous iodinated contrast for CT imaging of more than 100 mL, during an episode of acute kidney injury, was independently associated with worse renal outcomes and less renal recovery. • These adverse outcomes including renal replacement therapy were not more frequent in similar patients who received cumulatively 100 mL or less of CT contrast, compared with non-exposed patients. • More patients with CT contrast exposure during acute kidney injury experienced delayed renal recovery.
引用
- Chua HR, Low S, Murali TM, et al. Cumulative iodinated contrast exposure for computed tomography during acute kidney injury and major adverse kidney events. Eur Radiol. 2020. PMID: 33159575. doi:10.1007/s00330-020-07428-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。